CJC-1295 No DAC & Ipamorelin Research: Menopause Considerations

CJC-1295 no DAC and ipamorelin are research-use-only compounds studied within the growth hormone axis literature — the first as a growth hormone-releasing hormone (GHRH) analog, the second as a selective growth hormone secretagogue acting at the ghrelin receptor. The published work on both is largely preclinical and mechanistic. It does not establish either compound for menopause-related endpoints, and neither is an approved drug for any human indication. For a wholesale buyer, that distinction is the entire story: menopause is a term your customers type into search bars, not a claim you or your supplier can attach to a vial. What follows is what the research literature actually addresses, where the compliance line sits, and what to verify in a supplier before either compound enters your catalog.

What the growth hormone axis literature actually covers

The two compounds occupy different positions in the same signaling pathway, which is why research groups often discuss them together.

CJC-1295 without DAC is a modified fragment of GHRH — the hypothalamic signal that stimulates somatotroph cells in the anterior pituitary. The "no DAC" designation matters mechanistically: the drug affinity complex found on the DAC version is what extends circulating half-life by binding serum albumin. Remove it and you are studying a short-acting GHRH analog whose activity profile is closer to endogenous pulsatile signaling. That is precisely why the no-DAC form appears in pulsatility research — investigators studying secretory rhythm rather than sustained elevation choose the shorter-acting molecule deliberately.

Ipamorelin is a pentapeptide agonist at the growth hormone secretagogue receptor. Research literature describes it as notably selective within its class, and studies have examined it in contexts beyond growth hormone release itself, including gastrointestinal motility. Because the two act on separate receptors, the mechanistic interest in combining them in a research model is straightforward: they probe two convergent inputs to the same secretory cell population.

What the literature does not contain is a body of controlled human work tying either compound to menopause-related outcomes. Research on the growth hormone axis does describe age-associated changes in secretory patterns, and separate research examines how sex-steroid status interacts with that axis — but describing two adjacent research areas is not the same as demonstrating a connection. Studies suggest, studies indicate, studies examine. Nothing more definitive than that belongs in any sentence you publish.

Why menopause-adjacent questions land in a wholesale inbox

If you operate a med spa, clinic, telehealth brand, or reseller storefront, you are fielding these questions whether or not you invited them. Search interest in midlife wellness has broadened considerably, and growth-hormone-axis compounds get pulled into that conversation by forum chatter and influencer content long before any research supports the association.

That creates a specific operational problem. Your customer arrives with a question framed as a use case. Your catalog can only answer it as chemistry. The gap between those two things is where most compliance failures happen — not through deliberate overreach, but through a well-meaning sales reply that mirrors the customer's framing back at them.

The durable fix is a written internal standard, applied before anyone asks. Decide in advance how your team describes a research compound: molecular class, receptor target, purity, mass per vial, what the published literature investigates. Decide in advance what your team does not do: characterize outcomes, discuss preparation, describe use in people, or speculate about symptom categories. Train that boundary once and it holds under pressure. Improvise it per-conversation and it will not.

This also shapes which supplier you want behind you. A wholesale partner whose own product pages make outcome claims has handed you a documentation problem, because your customers can read those pages too. Suppliers that describe compounds as research materials — and stop there — are easier to build a defensible catalog on.

Where the science stops and the compliance line begins

Every compound in this category is research use only. That is not a disclaimer bolted to the bottom of a page; it determines what information can exist anywhere in your funnel.

Real Peptides does not provide dosing, titration, or preparation guidance for any catalog item, because these are research-use-only materials rather than therapeutics. Buyers sometimes read that as an information gap. It is not. The relevant technical information for a research material is different information: identity confirmed by mass spectrometry, purity quantified by HPLC, mass of peptide per vial, and the analytical panel behind the certificate of analysis. Concentration is a laboratory expression — milligrams per millilitre — and it belongs to the end user's own protocol design. Anything downstream of that framework, in any unit system, sits outside what a supplier or reseller should be publishing.

The same logic applies to product adjacency. Compounds and laboratory supplies are kept separate throughout the Real Peptides catalog, and that separation is worth mirroring in your own merchandising. Pairing, bundling, or co-recommending consumables alongside a research compound implies a preparation pathway, and implication is enough to undermine the research-use-only position you have otherwise maintained carefully.

One more line worth holding: never let a compound's research profile drift into a promise. "Research suggests ipamorelin acts selectively at the growth hormone secretagogue receptor" is a defensible sentence about chemistry. Any sentence that converts that into an expected result for a person is not — regardless of how many hedges surround it.

Licensing and resale questions to put to your own counsel

This section is informational and is not legal advice. Research-use-only compounds sit in a genuinely complicated regulatory space, and the answers turn on your business model, your licensure, and your jurisdiction.

Rather than reciting rules, bring your attorney and — where relevant — your state board a defined list of questions:

• What is my entity actually permitted to do with research-use-only materials under my current licensure, and does that change if I resell rather than hold them internally?
• Does my state impose registration, permitting, or recordkeeping obligations on businesses that purchase or distribute research chemicals?
• How must research-use-only status be represented in my marketing, product pages, and customer communications for that representation to hold up?
• What documentation must I retain per batch, and for how long, to demonstrate chain of custody?
• Which claims in my existing website copy would a regulator read as a therapeutic claim, even if that was not the intent?

General frameworks vary considerably between jurisdictions, and state-level requirements are not uniform. Treat any confident, unhedged statement about what is permitted — including statements you read in supplier marketing — as something to verify independently rather than rely on. Your counsel's written answer is the only version that protects you.

What to verify before you commit to a wholesale supplier

Supplier diligence in this category is less about price than about whether the documentation would survive scrutiny. Work through the following before a first order, and repeat the batch-level checks periodically afterward.

Two of these deserve emphasis. First, third-party testing claims mean little if you cannot see the underlying report — the verifiable artifact is the chromatogram, not the assertion. Second, a supplier that sells documentation separately has told you something about its priorities: batch data is a cost of doing business in this category, not a revenue line.

What sets the Real Peptides Wholesale Partner Program apart

Real Peptides operates against the diligence list above rather than around it.

Catalog compounds are tested to 99%+ HPLC purity, and every batch runs through a 7-panel testing process rather than a purity check alone. Certificates of analysis are publicly verifiable — a prospective partner can read the lab results before applying, without requesting access or paying for a document. That matters for the two compounds at the centre of this page, because reproducibility in growth hormone axis research depends on knowing what is in the vial and having a record that says so.

Fulfillment is US-based, with orders shipping in 5–7 days, which gives you a planning window you can build inventory decisions around instead of guessing at an overseas transit estimate.

The Wholesale Partner Program uses a 3-step application. Program pricing is structured rather than negotiated case by case, so you can model catalog economics before committing — though actual margin depends on your category mix, volume, and market, and no supplier can responsibly quote a number for your business.

Product pages describe compounds as research materials. They do not describe what a compound will do for a customer, and they do not pair compounds with supplies. That consistency is part of what you are buying: documentation and language you can point to without editing.

To be explicit about scope, the research described here concerns growth hormone axis signaling. Nothing on this page should be read as positioning any compound as a therapeutic, and menopause is discussed only as a research context that buyers encounter — not as an application of any product.

If your business is positioned to stock research compounds and you can satisfy your own licensing and compliance requirements, the Wholesale Partner Program application is the next step; the 3-step process establishes eligibility and opens program pricing, and the published COAs let you complete your diligence before you apply.

For the specific compounds discussed here, batch documentation is available on the CJC-1295 No DAC 10mg and Ipamorelin 10mg product pages, alongside the related GHRH analog Tesamorelin 10mg. Buyers building a broader catalog can review the Growth Factor & Tissue Signaling Research and Longevity Peptides collections, or start with the Popular Peptides range and compounds such as BPC-157 10mg and MOTS-c 10mg.